In O
addition O
, O
when O
used O
together O
IL B
- I
2 I
and O
IL B
- I
12 I
synergized O
in O
the O
induction O
of O
IFN B
- I
gamma I
and O
GM B
- I
CSF I
and O
this O
synergy O
was O
attributed O
to O
an O
increased O
accumulation O
and O
stability O
of O
the O
IFN B
- I
gamma I
and I
GM I
- I
CSF I
mRNAs I
. O

A O
Myc B
- I
associated I
zinc I
finger I
protein I
binding I
site I
is O
one O
of O
four O
important O
functional B
regions I
in O
the O
CD4 B
promoter I
. O

We O
provide O
evidence O
for O
an O
additional O
binding B
site I
, O
the O
MIP B
- I
1 I
alpha I
nuclear I
protein I
( I
MNP I
) I
site I
, O
which O
overlaps O
the O
ICK B
- I
1 I
site I
. O

We O
have O
recently O
found O
a O
novel O
conserved B
motif I
in O
the O
promoters B
of O
several O
T B
- I
cell I
- I
expressed I
cytokines I
[ O
human B
interleukin I
- I
2 I
, I
- I
4 I
, I
- I
5 I
and I
- I
13 I
and O
human B
and I
mouse I
granulocyte I
/ I
macrophage I
- I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
] O
. O

We O
have O
recently O
found O
a O
novel O
conserved B
motif I
in O
the O
promoters B
of O
several O
T B
- I
cell I
- I
expressed I
cytokines I
[ O
human B
interleukin I
- I
2 I
, I
- I
4 I
, I
- I
5 I
and I
- I
13 I
and O
human B
and I
mouse I
granulocyte I
/ I
macrophage I
- I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
] O
. O

Antigen O
complexed O
with O
major B
histocompatibility I
complex I
class I
I I
or I
II I
molecules I
on O
the O
surface O
of O
antigen O
presenting O
cells O
interacts O
with O
the O
T B
cell I
receptor I
( O
TCR B
) O
on O
the O
surface O
of O
T O
cells O
and O
initiates O
an O
activation O
cascade O
. O

Costimulatory O
signals O
, O
such O
as O
activation O
of O
the O
CD28 B
cell I
surface I
molecule I
on O
T O
cells O
, O
lead O
to O
activation O
through O
a O
distinct O
region O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
promoter I
. O

Multiple O
signals O
are O
required O
for O
function O
of O
the O
human B
granulocyte I
- I
macrophage I
colony I
- I
stimulating I
factor I
gene I
promoter I
in O
T O
cells O
. O

Here O
, O
we O
demonstrate O
that O
CIITA B
is O
an O
MHC B
class I
II I
gene I
- I
specific I
transcription I
activator I
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

Human O
peripheral O
blood O
monocytes O
responded O
to O
stimulation O
of O
platelet B
- I
activating I
factor I
( O
PAF B
) O
with O
up O
- O
regulation O
of O
the O
transcript O
for O
heparin B
- I
binding I
epidermal I
growth I
factor I
- I
like I
growth I
factor I
( O
HB B
- I
EGF I
) O
, O
a O
potent B
mitogen I
for O
vascular O
smooth O
muscle O
cells O
. O

Because O
these O
are O
the O
characteristics O
of O
a O
signal B
transducer I
and I
activator I
of I
transcription I
( I
Stat I
) I
protein I
, O
we O
determined O
whether O
antibodies B
to I
Stat I
proteins I
will O
interfere O
with O
gel O
mobility O
shift O
and O
found O
that O
antibodies B
to I
IL I
- I
4 I
Stat I
, O
also O
known O
as O
Stat6 B
, O
but O
not O
antibodies B
to O
other O
Stat B
proteins I
, O
interfere O
with O
the O
formation O
of O
the O
IL B
- I
4 I
NAF I
complex I
. O

When O
transfected O
into O
K562 O
cells O
, O
which O
express O
zeta B
- I
globin I
, O
comparable O
amounts O
of O
activity O
were O
obtained O
from O
the O
- B
557 I
and I
- I
417 I
zeta I
- I
luciferase I
constructs I
and O
the O
alpha B
- I
luciferase I
constructs I
when O
no O
enhancers B
or O
the O
alpha B
- I
globin I
locus I
enhancers I
were O
used O
. O

To O
address O
this O
issue O
, O
mutationally O
active O
PKC B
- I
alpha I
, I
- I
epsilon I
, I
or I
- I
zeta I
have O
been O
transfected O
into O
T O
cells O
and O
the O
consequences O
for O
T O
cell O
activation O
determined O
. O

Signaling O
by O
a O
wide O
variety O
of O
cytokines B
, O
including O
interferons B
, O
interleukins B
, O
and O
growth B
factors I
, O
involves O
activation O
of O
JAK B
kinases I
and O
Stat B
( I
Signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

Here O
we O
show O
that O
the O
lymphoid B
- I
specific I
transcription I
factor I
Oct I
- I
2A I
plays O
a O
critical O
role O
in O
HLA B
- I
DRA I
gene I
expression O
in O
class O
II O
- O
positive O
B O
cell O
lines O
, O
and O
that O
the O
high B
mobility I
group I
protein I
( O
HMG B
) O
I B
/ I
Y I
binds O
to O
multiple O
sites O
within O
the O
DRA B
promoter I
, O
including O
the O
Oct B
- I
2A I
binding I
site I
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV B
- I
encoded I
nuclear I
antigens I
( O
EBNA1 B
, I
2 I
, I
3A I
, I
3B I
, I
3C I
, I
- I
LP I
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B B
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

Expression O
of O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
latent I
membrane I
protein I
1 I
( I
LMP I
- I
1 I
) I
oncogene I
is O
regulated O
by O
the O
EBV B
nuclear I
protein I
2 I
( I
EBNA I
- I
2 I
) I
transactivator I
. O

Expression O
of O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
latent I
membrane I
protein I
1 I
( I
LMP I
- I
1 I
) I
oncogene I
is O
regulated O
by O
the O
EBV B
nuclear I
protein I
2 I
( I
EBNA I
- I
2 I
) I
transactivator I
. O

The O
minimal B
EBNA I
- I
2 I
- I
responsive I
LMP I
- I
1 I
promoter I
includes O
one O
J B
kappa I
- I
binding I
site I
, O
and O
we O
now O
show O
that O
mutation O
of O
that O
site O
, O
such O
that O
J B
kappa I
can O
not O
bind O
, O
reduces O
EBNA B
- I
2 I
responsiveness O
by O
60 O
% O
. O

To O
identify O
other O
factors O
which O
interact O
with O
the O
LMP B
- I
1 I
EBNA I
- I
2 I
response I
element I
( O
E2RE B
) O
, O
a O
- B
236 I
/ I
- I
145 I
minimal I
E2RE I
was O
used O
as O
a O
probe O
in O
an O
electrophoretic O
mobility O
shift O
assay O
. O

The O
role O
of O
NFATp B
in O
cyclosporin B
A I
- I
sensitive I
tumor I
necrosis I
factor I
- I
alpha I
gene I
transcription O
. O

We O
also O
examined O
the O
function O
of O
the O
IL B
- I
3 I
CK I
- I
1 I
/ I
CK I
- I
2 I
elements I
that O
are O
present O
in O
many O
cytokine B
genes I
and O
found O
that O
they O
acted O
as O
a O
repressor O
of O
basal O
level O
expression O
when O
cloned O
upstream O
of O
a O
heterologous B
promoter I
but O
were O
also O
inducible O
by O
PMA O
/ B
PHA I
. O

Using O
a O
highly O
sensitive O
mutation O
screening O
assay O
of O
the O
DNA B
- I
and I
the I
steroid I
- I
binding I
region I
, O
none O
of O
the O
treated O
patients O
revealed O
any O
mutation O
, O
suggesting O
that O
the O
glucocorticoid B
receptor I
in O
the O
CLL O
patients O
tested O
is O
not O
altered O
in O
these O
domains O
. O

Methylation O
studies O
indicated O
that O
the O
tal B
- I
15 I
' I
GC I
- I
rich I
region I
behaves O
like O
a O
CpG B
island I
, O
hypomethylated O
in O
normal O
cells O
, O
and O
methylated O
de O
novo O
on O
transcriptionally B
inactive I
alleles I
in O
established O
cell O
lines O
. O

E2F B
- I
1 I
and I
DP I
- I
1 I
mRNAs I
were O
not O
detectable O
in O
granulocytes O
, O
monocytes O
and O
resting O
T O
- O
lymphocytes O
but O
were O
induced O
after O
the O
mitogenic O
stimulation O
of O
T O
- O
lymphocytes O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
two O
interactive O
mechanisms O
regulate O
monocytic B
I I
kappa I
B I
alpha I
/ I
MAD I
- I
3 I
mRNA I
levels O
. O

Here O
, O
we O
report O
that O
stimulation O
through O
the O
IL B
- I
2R I
induced O
tyrosine O
phosphorylation O
and O
subsequent O
nuclear O
translocation O
of O
stat3 B
, O
a O
newly O
identified O
member O
of O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
family I
of O
proteins O
. O

Therefore O
we O
investigated O
the O
modifications O
imposed O
on O
NF B
- I
kappa I
B I
/ I
I I
kappa I
B I
components I
following O
stimulation O
and O
show O
that O
the O
final O
step O
of O
NF B
- I
kappa I
B I
induction O
in O
vivo O
involves O
phosphorylation O
of O
several O
members O
of O
the O
NF B
- I
kappa I
B I
/ I
I I
kappa I
B I
protein I
families I
. O

Therefore O
we O
investigated O
the O
modifications O
imposed O
on O
NF B
- I
kappa I
B I
/ I
I I
kappa I
B I
components I
following O
stimulation O
and O
show O
that O
the O
final O
step O
of O
NF B
- I
kappa I
B I
induction O
in O
vivo O
involves O
phosphorylation O
of O
several O
members O
of O
the O
NF B
- I
kappa I
B I
/ I
I I
kappa I
B I
protein I
families I
. O

The O
regulation O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
activation O
by O
the O
T B
cell I
receptor I
( I
TcR I
) I
/ I
CD3 I
complex I
in O
primary O
human O
T O
cells O
has O
been O
studied O
at O
various O
times O
after O
activation O
. O

The O
regulation O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
activation O
by O
the O
T B
cell I
receptor I
( I
TcR I
) I
/ I
CD3 I
complex I
in O
primary O
human O
T O
cells O
has O
been O
studied O
at O
various O
times O
after O
activation O
. O

The O
cis B
- I
acting I
region I
, O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
( O
positions B
- I
95 I
and O
- B
73 I
) O
, O
within O
the O
murine B
GM I
- I
CSF I
gene I
promoter I
is O
required O
for O
maximal O
induction O
by O
stimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
in O
T O
cells O
. O

We O
report O
here O
that O
three O
copies O
of O
the O
GC B
- I
box I
can O
functionally O
compensate O
for O
the O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
region I
, O
suggesting O
that O
the O
GC O
- O
motif O
can O
function O
independently O
of O
the O
GM B
- I
kappa I
B I
motif I
. O

OAP B
confers O
to O
Oct B
- I
2 I
responsivity O
to O
both O
TPA O
/ O
Ca2 O
+ O
and O
RA O
, O
since O
specific O
mutations O
of O
the O
AP B
- I
1 I
/ I
OAP I
- I
binding I
site I
significantly O
reduce O
the O
transactivation O
by O
Oct B
- I
2 I
in O
response O
to O
TPA O
and O
Ca2 O
+ O
and O
abolish O
the O
inhibition O
by O
RA O
. O

PMA B
- I
but I
not I
TG I
- I
induced I
IL I
- I
2R I
alpha I
is O
inhibited O
by O
the O
PKC B
inhibitor O
H7 O
, O
whereas O
TG B
- I
but I
not I
PMA I
- I
induced I
IL I
- I
2R I
alpha I
was O
inhibited O
by O
cholera O
toxin O
, O
forskolin O
and O
1 O
, O
9 O
- O
dideoxy O
forskolin O
. O

PMA B
- I
but I
not I
TG I
- I
induced I
IL I
- I
2R I
alpha I
is O
inhibited O
by O
the O
PKC B
inhibitor O
H7 O
, O
whereas O
TG B
- I
but I
not I
PMA I
- I
induced I
IL I
- I
2R I
alpha I
was O
inhibited O
by O
cholera O
toxin O
, O
forskolin O
and O
1 O
, O
9 O
- O
dideoxy O
forskolin O
. O

Calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
II I
downregulates O
both O
calcineurin O
and O
protein O
kinase O
C O
- O
mediated O
pathways O
for O
cytokine B
gene I
transcription O
in O
human O
T O
cells O
. O

H582 O
and O
HuT102 O
were O
also O
negative O
for O
the O
LFA B
- I
I I
alpha I
chain I
( I
CDIIa I
) I
mRNA I
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

The O
interleukin B
2 I
receptor I
alpha I
- I
chain I
( I
IL I
- I
2R I
alpha I
) I
gene I
is O
rapidly O
and O
potently O
induced O
in O
T O
cells O
in O
response O
to O
mitogenic O
stimuli O
. O

Aspirin O
- O
like O
drugs O
can O
protect O
human O
T O
lymphocytes O
against O
benzoquinone O
cytotoxicity O
: O
evidence O
for O
a O
NAD B
( I
P I
) I
H I
: I
quinone I
reductase I
- O
dependent O
mechanism O
. O

Two O
cis B
- I
acting I
elements I
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
and O
CLE0 B
, O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
gene I
are O
required O
for O
maximal O
induction O
in O
Jurkat O
T O
cells O
by O
costimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
Ca2 O
+ O
ionophore O
( O
A23187 O
) O
. O

Two O
cis B
- I
acting I
elements I
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
and O
CLE0 B
, O
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
gene I
are O
required O
for O
maximal O
induction O
in O
Jurkat O
T O
cells O
by O
costimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
Ca2 O
+ O
ionophore O
( O
A23187 O
) O
. O

OBJECTIVE O
: O
To O
determine O
whether O
activation O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
replication O
in O
tumour O
cells O
of O
AIDS O
- O
related O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ARNHL O
) O
is O
correlated O
with O
CD4 B
+ I
cell O
counts O
and O
influences O
antibody O
response O
to O
EBV O
[ O
anti B
- I
Z I
Epstein I
- I
Barr I
replicative I
activator I
( O
ZEBRA B
) O
, O
anti B
- I
early I
antigen I
( O
EA B
) O
, O
anti B
- I
viral I
capsid I
antigen I
( O
VCA B
) O
] O
. O

We O
have O
identified O
a O
` B
` I
two I
- I
handed I
' I
' I
zinc I
finger I
protein I
, O
denoted O
ZEB B
, O
the O
DNA O
- O
binding O
specificity O
of O
which O
mimics O
that O
of O
the O
cellular B
repressor I
. O

Two O
nuclear B
factor I
NF I
- I
IL6 I
( O
positions O
- B
153 I
to I
- I
145 I
and O
- O
83 O
to O
- O
75 O
) O
and O
one O
nuclear B
factor I
NF I
- I
kappa I
B I
( I
positions I
- I
72 I
to I
- I
63 I
) I
motifs I
are O
present O
within O
this O
fragment O
. O

We O
conclude O
that O
the O
NF B
- I
IL6 I
and I
NF I
- I
kappa I
B I
sites I
mediate O
IL B
- I
6 I
induction O
in O
response O
to O
both O
LPS O
and O
LAM B
, O
acting O
as O
bacterial B
or I
mycobacterial I
response I
elements I
. O

The O
expression O
of O
the O
p50 B
and I
p65 I
NF I
- I
kappa I
B I
subunits I
was O
also O
shown O
to O
be O
regulated O
differentially O
after O
exposures O
to O
1 O
. O
0 O
and O
2 O
. O
0 O
Gy O
. O

Examination O
of O
the O
primary O
amino O
acid O
sequence O
of O
this O
protein O
indicates O
that O
it O
is O
a O
member O
of O
the O
signal B
transducers I
and I
activators I
of I
transcription I
( I
Stat I
) I
family I
of O
DNA B
binding I
proteins I
, O
hereby O
designated O
IL B
- I
4 I
Stat I
. O

Analysis O
of O
the O
chromatin O
organization O
of O
the O
integrated O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
genome I
has O
previously O
revealed O
a O
major B
constitutive I
DNase I
I I
- I
hypersensitive I
site I
associated O
with O
the O
pol B
gene I
( O
E O
. O
Verdin O
, O
J O
. O
Virol O
. O
65 O
: O
6790 O
- O
6799 O
, O
1991 O
) O
. O

The O
role O
of O
the O
human B
immunodeficiency I
virus I
( I
HIV I
- I
1 I
) I
Nef I
protein I
in O
T O
cell O
activation O
pathways O
was O
investigated O
using O
a O
Jurkat O
CD4 O
+ O
cell O
line O
stably O
transfected O
with O
a O
Nef O
expression O
vector O
. O

Acetylsalicylic O
acid O
and O
sodium O
salicylate O
inhibit O
LPS O
- O
induced O
NF B
- I
kappa I
B I
/ I
c I
- I
Rel I
nuclear O
translocation O
, O
and O
synthesis O
of O
tissue B
factor I
( O
TF B
) O
and O
tumor B
necrosis I
factor I
alfa I
( O
TNF B
- I
alpha I
) O
in O
human O
monocytes O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

In O
most O
cell O
lines O
, O
proteins O
of O
molecular O
weight O
49 O
and O
44 O
kDa O
were O
found O
, O
however O
two O
myeloid O
cell O
lines O
expressed O
only O
lower O
molecular B
weight I
species I
of I
24 I
and I
22 I
kDa I
. O

Furthermore O
, O
the O
physical O
interaction O
of O
Tax B
with O
p100 B
leads O
to O
the O
inhibition O
of O
Tax B
- O
induced O
activation O
of O
the O
HTLV O
- O
I O
and O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeats I
, O
reflecting O
p100 B
- O
mediated O
cytoplasmic O
sequestration O
of O
the O
normally O
nuclearly O
expressed O
Tax B
protein I
. O

The O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
transforming I
protein I
LMP1 I
appears O
to O
be O
a O
constitutively B
activated I
tumor I
necrosis I
factor I
receptor I
( O
TNFR B
) O
on O
the O
basis O
of O
an O
intrinsic O
ability O
to O
aggregate O
in O
the O
plasma O
membrane O
and O
an O
association O
of O
its O
cytoplasmic B
carboxyl I
terminus I
( O
CT B
) O
with O
TNFR B
- I
associated I
factors I
( O
TRAFs B
) O
. O

The O
gene O
encoding O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- I
specific I
dUTPase I
was O
amplified O
from O
virus B
DNA I
by O
PCR O
. O

Two O
pp56 B
( I
lck I
) I
mutants I
lacking O
either O
the O
entire O
catalytic B
domain I
or O
the O
entire O
NH2 B
regulatory B
domain I
were O
generated O
, O
and O
their O
abilities O
to O
trigger O
transactivation O
of O
the O
TCR B
- I
regulated I
nuclear I
factor I
of I
activated I
T I
cells I
( I
NF I
- I
AT I
) I
region I
of O
the O
IL B
- I
2 I
promoter I
were O
compared O
. O

The O
macrophage B
colony I
- I
stimulating I
factor I
( I
M I
- I
CSF I
) I
receptor I
is O
expressed O
in O
a O
tissue O
- O
specific O
fashion O
from O
two O
distinct O
promoters B
in O
monocytes O
/ O
macrophages O
and O
the O
placenta O
. O

Cell O
specific O
expression O
of O
human B
Bruton I
' I
s I
agammaglobulinemia I
tyrosine I
kinase I
gene I
( O
Btk B
) O
is O
regulated O
by O
Sp1 B
- I
and O
Spi B
- I
1 I
/ I
PU I
. I
1 I
- I
family I
members I
. O

Cell O
specific O
expression O
of O
human B
Bruton I
' I
s I
agammaglobulinemia I
tyrosine I
kinase I
gene I
( O
Btk B
) O
is O
regulated O
by O
Sp1 B
- I
and O
Spi B
- I
1 I
/ I
PU I
. I
1 I
- I
family I
members I
. O

Furthermore O
, O
overexpression O
and O
constitutive O
nuclear O
localization O
of O
NF B
- I
AT I
, O
but O
not O
Jun B
, I
Fos I
, I
NF I
- I
kappaB I
, I
Oct I
or I
Ets I
family I
members I
, O
renders O
the O
interleukin B
- I
2 I
enhancer I
in O
Jurkat O
T O
lymphocytes O
resistant O
to O
FK506 O
and O
cyclosporin O
A O
. O

In O
lymphoid O
cell O
lines O
only O
, O
the O
E B
( I
gre I
) I
- I
binding I
protein I
complexes I
included O
ALF1 B
or O
HEB B
and O
E2A B
basic I
helix I
- I
loop I
- I
helix I
proteins I
. O

In O
lymphoid O
cell O
lines O
only O
, O
the O
E B
( I
gre I
) I
- I
binding I
protein I
complexes I
included O
ALF1 B
or O
HEB B
and O
E2A B
basic I
helix I
- I
loop I
- I
helix I
proteins I
. O

Transient O
expression O
of O
NFATc B
. I
beta I
was O
capable O
of O
activating O
an O
interleukin B
- I
2 I
NFAT I
- I
driven I
reporter I
gene I
in O
stimulated O
Jurkat O
cells O
in O
a O
CsA O
- O
sensitive O
manner O
. O

The O
proximal B
sequence I
element I
( I
PSE I
) I
- I
binding I
transcription I
factor I
( O
PTF B
) O
, O
which O
binds O
the O
PSE B
of O
both O
RNA B
polymerase I
II I
- I
and I
RNA I
polymerase I
III I
- I
transcribed I
mammalian I
small I
nuclear I
RNA I
( I
snRNA I
) I
genes I
, O
is O
essential O
for O
their O
transcription O
. O

The O
proximal B
sequence I
element I
( I
PSE I
) I
- I
binding I
transcription I
factor I
( O
PTF B
) O
, O
which O
binds O
the O
PSE B
of O
both O
RNA B
polymerase I
II I
- I
and I
RNA I
polymerase I
III I
- I
transcribed I
mammalian I
small I
nuclear I
RNA I
( I
snRNA I
) I
genes I
, O
is O
essential O
for O
their O
transcription O
. O

The O
lymphocyte B
- I
specific I
immunoglobulin I
mu I
heavy I
- I
chain I
gene I
intronic I
enhancer I
is O
regulated O
by O
multiple O
nuclear B
factors I
. O

Mechanisms O
of O
transactivation O
by O
nuclear B
factor I
of I
activated I
T I
cells I
- I
1 I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
- I
family I
proteins I
( O
NFAT1 B
/ I
NFATp I
, O
NFATc B
, O
NFAT3 B
, O
and O
NFAT4 B
/ I
NFATx I
/ I
NFATc3 I
) O
play O
a O
key O
role O
in O
the O
transcription O
of O
cytokine B
genes I
and O
other O
genes O
during O
the O
immune O
response O
. O

A O
2 B
- I
bp I
mutation I
within O
the O
CBF B
site O
resulted O
in O
a O
2 O
- O
3 O
- O
fold O
decrease O
in O
the O
activities O
of O
both O
a O
69 B
- I
bp I
proximal I
promoter I
fragment I
and O
a O
627 B
- I
bp I
full I
- I
length I
promoter I
fragment I
. O

The O
preferential O
induction O
of O
c B
- I
jun I
by O
H2O2 O
did O
not O
represent O
redox O
stabilization O
of O
mRNA B
transcripts I
, O
and O
oxidative O
signals O
closely O
resembled O
PHA O
/ O
PMA O
stimulation O
by O
effectively O
transactivating O
the O
full O
length O
c B
- I
jun I
promoter O
via O
the O
proximal B
jun1 I
tumor I
promoter I
- I
responsive I
element I
( I
TRE I
) I
- I
like I
promoter I
element I
. O

Early O
studies O
in O
murine O
T O
cell O
lines O
indicated O
that O
transcriptional O
transactivation O
functions O
encoded O
in O
the O
glucocorticoid B
receptor I
( I
GR I
) I
N I
- I
terminal I
domain I
are O
required O
for O
glucocorticoid O
- O
mediated O
apoptosis O
. O

Gel O
mobility O
shift O
and O
immunoprecipitation O
analyses O
revealed O
that O
in O
addition O
to O
activating O
STAT3 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
) O
and O
STAT5 B
, O
IL B
- I
2 I
induced O
tyrosine O
and O
serine O
phosphorylation O
of O
STAT1 B
alpha I
, O
which O
formed O
IFN B
- I
gamma I
- I
activated I
sequence I
- I
binding I
complexes I
by O
itself O
and O
with O
STAT3 B
. O

Gel O
mobility O
shift O
and O
immunoprecipitation O
analyses O
revealed O
that O
in O
addition O
to O
activating O
STAT3 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
) O
and O
STAT5 B
, O
IL B
- I
2 I
induced O
tyrosine O
and O
serine O
phosphorylation O
of O
STAT1 B
alpha I
, O
which O
formed O
IFN B
- I
gamma I
- I
activated I
sequence I
- I
binding I
complexes I
by O
itself O
and O
with O
STAT3 B
. O

Translocation B
( I
3 I
; I
14 I
) I
( I
q27 I
; I
q11 I
) I
: O
a O
new O
variant O
translocation O
in O
a O
patient O
with O
non O
- O
Hodgkin O
' O
s O
lymphoma O
of O
B O
- O
cell O
type O
with O
BCL6 B
rearrangement O
. O

Biochemical O
analysis O
of O
the O
region O
- B
158 I
/ I
- I
90 I
revealed O
a O
binding O
site O
for O
transcription B
factors I
of O
the O
polyomavirus B
enhancer I
- I
binding I
protein I
2 I
/ I
core I
- I
binding I
factor I
( I
PEBP2 I
/ I
CBF I
) I
family I
at O
position B
- I
103 I
. O

Based O
on O
the O
presence O
of O
T B
cell I
receptor I
- I
beta I
( I
TcR I
- I
beta I
) I
gene I
rearrangements I
in O
L428 O
and O
HDLM O
- O
1 O
cells O
, O
the O
expression O
of O
CD2 B
in O
HDLM O
- O
1 O
cells O
, O
and O
the O
presence O
of O
immunoglobulin B
heavy I
- I
chain I
( I
IgH I
) I
gene I
rearrangement I
in O
KM O
- O
H2 O
cells O
, O
some O
researchers O
have O
concluded O
that O
these O
long O
- O
term O
cell O
lines O
derived O
from O
patients O
with O
Hodgkin O
' O
s O
disease O
are O
lymphoid O
in O
nature O
. O

Based O
on O
the O
presence O
of O
T B
cell I
receptor I
- I
beta I
( I
TcR I
- I
beta I
) I
gene I
rearrangements I
in O
L428 O
and O
HDLM O
- O
1 O
cells O
, O
the O
expression O
of O
CD2 B
in O
HDLM O
- O
1 O
cells O
, O
and O
the O
presence O
of O
immunoglobulin B
heavy I
- I
chain I
( I
IgH I
) I
gene I
rearrangement I
in O
KM O
- O
H2 O
cells O
, O
some O
researchers O
have O
concluded O
that O
these O
long O
- O
term O
cell O
lines O
derived O
from O
patients O
with O
Hodgkin O
' O
s O
disease O
are O
lymphoid O
in O
nature O
. O

Transcriptional O
activation O
of O
RNA B
polymerase I
III I
- I
dependent I
genes I
by O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
1 I
tax I
protein I
. O

A O
variety O
of O
cytokines B
and O
growth B
factors I
act O
through O
an O
induction O
of O
gene O
expression O
mediated O
by O
a O
family O
of O
latent B
transcription I
factors I
called O
STAT B
( I
signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

Although O
a O
13 B
- I
kilobase I
- I
pair I
( I
kb I
) I
human I
c I
- I
fes I
transgene I
exhibits O
high O
levels O
of O
expression O
in O
mice O
, O
the O
sequences O
that O
confer O
myeloid O
- O
cell O
- O
specific O
expression O
of O
the O
human B
c I
- I
fes I
gene I
have O
not O
been O
defined O
. O

IL B
- I
10 I
markedly O
reduces O
nuclear O
factor O
( B
NF I
) I
- I
kappa I
B I
/ I
Rel I
nuclear O
activity O
induced O
in O
PBMC O
by O
stimulation O
with O
the O
anti B
- I
CD3 I
mAb I
OKT3 B
. O

As O
judged O
by O
supershifting O
the O
DNA B
- I
protein I
complexes I
with O
Abs B
recognizing O
specific O
components O
of O
the O
NF B
- I
kappa I
B I
/ I
Rel I
protein I
family I
, O
the O
p50 B
/ I
p65 I
( O
Rel B
A I
) O
heterodimeric O
form O
of O
NF B
- I
kappa I
B I
is O
primarily O
affected O
. O

Interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
- B
reporter I
gene I
behavior O
closely O
parallels O
the O
endogenous B
gene I
in O
response O
to O
T B
cell I
receptor I
and O
costimulatory O
signals O
. O

After O
treatment O
of O
APL O
cells O
with O
AM580 O
either O
alone O
or O
in O
combination O
with O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
, O
the O
compound O
induces O
granulocytic O
maturation O
, O
as O
assessed O
by O
determination O
of O
the O
levels O
of O
leukocyte B
alkaline I
phosphatase I
, I
CD11b I
, I
CD33 I
, I
and I
G I
- I
CSF I
receptor I
mRNA I
, O
at O
concentrations O
that O
are O
10 O
- O
to O
100 O
- O
fold O
lower O
than O
those O
of O
ATRA O
necessary O
to O
produce O
similar O
effects O
. O

Inhibition O
of O
vitamin B
D I
receptor I
- I
retinoid I
X I
receptor I
- I
vitamin I
D I
response I
element I
complex I
formation O
by O
nuclear O
extracts O
of O
vitamin O
D O
- O
resistant O
New O
World O
primate O
cells O
. O

We O
have O
isolated O
a O
novel B
cDNA I
clone I
encoding O
interferon B
( I
IFN I
) I
consensus I
sequence I
- I
binding I
protein I
in O
adult O
T O
- O
cell O
leukemia O
cell O
line O
or O
activated O
T O
cells O
( O
ICSAT B
) O
; O
this O
protein O
is O
the O
human O
homolog O
of O
the O
recently O
cloned O
Pip B
/ I
LSIRF I
. O

Here O
, O
we O
describe O
the O
effect O
of O
383 B
- I
bp I
( I
delta383 I
) I
and I
99 I
- I
bp I
( I
delta99 I
) I
sequences I
containing O
the O
PYBF B
- I
binding I
site I
on O
transcription O
from O
various O
globin O
and O
non O
- O
globin O
promoters O
, O
using O
a O
transient O
assay O
with O
the O
cat B
reporter I
gene I
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
, O
a O
cell O
line O
with O
abundant O
PYBF B
activity O
. O

The O
Epstein B
- I
Barr I
virus I
- I
encoded I
nuclear I
antigen I
EBNA I
- I
5 I
accumulates O
in O
PML O
- O
containing O
bodies O
. O

Together O
, O
our O
results O
indicate O
that O
occupancy O
of O
the O
viral B
enhancer I
by O
NF B
- I
kappaB I
( I
p50 I
/ I
p65 I
) I
heterodimers I
is O
required O
for O
ongoing O
transcription O
of O
integrated O
HIV O
provirus O
in O
monocytes O
, O
even O
in O
cells O
chronically O
infected O
and O
permanently O
producing O
functional O
HIV B
Tat I
protein I
. O

Two O
explanations O
for O
hyporesponsiveness O
of O
the O
human B
iNOS I
promoter I
to O
LPS O
+ O
/ O
- O
IFN B
- I
gamma I
were O
found O
: O
( O
1 O
) O
multiple O
inactivating O
nucleotide O
substitutions O
in O
the O
human O
counterpart O
of O
the O
enhancer B
element I
that O
has O
been O
shown O
to O
regulate O
LPS O
/ O
IFN B
- I
gamma I
induced O
expression O
of O
the O
mouse B
iNOS I
gene I
; O
and O
( O
2 O
) O
and O
absence O
of O
one O
or O
more O
nuclear B
factors I
in O
human O
macrophages O
( O
e O
. O
g O
. O
, O
an O
LPS B
- I
inducible I
nuclear I
factor I
- I
kappa I
B I
/ I
Rel I
complex I
) O
, O
that O
is O
( O
are O
) O
required O
for O

Deletional O
and O
site O
- O
directed O
mutagenesis O
revealed O
the O
presence O
of O
multiple O
functionally O
critical O
cis B
elements I
within O
this O
region O
, O
one O
of O
which O
was O
a O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
consensus I
sequence I
. O

This O
raises O
the O
intriguing O
possibility O
that O
physical O
association O
of O
the O
HsN3 B
proteasome I
subunit I
with O
HTLV B
- I
I I
Tax I
coupled O
with O
the O
independent O
interaction O
of O
Tax B
with O
either O
p100 O
or O
p65 O
- O
I B
kappa I
B I
alpha I
targets O
these O
cytoplasmic B
NF I
- I
kappa I
B I
/ I
Rel I
complexes I
to O
the O
proteasome B
for O
processing O
. O

IL B
- I
4 I
activates O
gene O
expression O
by O
inducing O
tyrosine O
phosphorylation O
, O
homodimerization O
, O
and O
nuclear O
translocation O
of O
the O
latent B
transcription I
factor I
, O
STAT6 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
6 I
) O
. O

In O
this O
study O
, O
we O
analyzed O
the O
binding O
activity O
of O
IL B
- I
10 I
- I
and I
IFN I
- I
gamma I
- I
activated I
STAT I
molecules I
to O
two O
kinds O
of O
GAS B
- O
motif O
sequences O
. O

Here O
, O
we O
have O
readdressed O
the O
issue O
of O
CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
the O
72 B
- I
kDa I
major I
immediate I
- I
early I
protein I
( O
IE B
- I
1 I
) O
, O
which O
is O
nonstructural O
but O
is O
found O
very O
early O
and O
throughout O
the O
replicative O
cycle O
. O

Mutagenesis O
of O
NF B
kappa I
B I
or I
Sp I
- I
1 I
elements I
within O
the O
LTR B
resulted O
in O
no O
change O
in O
the O
ability O
of O
CD8 O
+ O
T O
cell O
supernatants O
to O
inhibit O
Tat O
- O
or O
mitogen O
- O
mediated O
LTR O
transcription O
. O

Nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
a O
redox B
sensitive I
cytosolic I
transcription I
factor I
. O

We O
also O
report O
that O
in O
RAW O
264 O
. O
7 O
cells O
, O
an O
E O
( O
2 O
) O
receptor O
- O
positive O
murine O
monocytic O
line O
, O
E O
( O
2 O
) O
downregulates O
cytokine O
- O
induced O
TNF B
gene O
expression O
by O
decreasing O
the O
activity O
of O
the O
Jun B
NH I
( I
2 I
) I
- I
terminal I
kinase I
( O
JNK B
) O
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

MBP B
also O
induced O
transient O
increases O
in O
mRNA B
for O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
- I
1alpha I
and O
MIP B
- I
1beta I
, O
but O
did O
not O
stimulate O
the O
release O
of O
either O
chemokine B
. O

DNase B
I I
footprinting O
identified O
several O
protected O
areas O
including O
Sp1 B
, I
Sp1 I
/ I
AP I
- I
2 I
, I
and I
cAMP I
response I
element I
( I
CRE I
) I
binding I
sites I
within O
the O
201 O
- O
bp O
core O
promoter O
region O
and O
Sp1 B
, I
NRE I
- I
2a I
, I
TCF I
- I
1 I
/ I
LEF I
- I
1 I
, I
and I
Sp1 I
/ I
NF I
- I
AT I
binding I
sites I
in O
the O
upstream B
regulatory I
region I
. O

DNase B
I I
footprinting O
identified O
several O
protected O
areas O
including O
Sp1 B
, I
Sp1 I
/ I
AP I
- I
2 I
, I
and I
cAMP I
response I
element I
( I
CRE I
) I
binding I
sites I
within O
the O
201 O
- O
bp O
core O
promoter O
region O
and O
Sp1 B
, I
NRE I
- I
2a I
, I
TCF I
- I
1 I
/ I
LEF I
- I
1 I
, I
and I
Sp1 I
/ I
NF I
- I
AT I
binding I
sites I
in O
the O
upstream B
regulatory I
region I
. O

In O
summary O
, O
we O
have O
identified O
a O
tissue B
- I
specific I
regulatory I
region I
5 O
' O
of O
the O
ecto B
- I
5 I
' I
- I
NT I
core I
promoter I
that O
requires O
the O
presence O
of O
a O
functional O
CRE B
site I
within O
the O
basal B
promoter I
for O
its O
suppressive O
activity O
. O

Here O
we O
provide O
novel O
evidence O
that O
AG O
- O
490 O
potently O
inhibits O
the O
autokinase O
activity O
of O
JAK3 B
and O
tyrosine O
phosphorylation O
and O
DNA O
binding O
of O
signal B
transducer I
and I
activator I
of I
transcription I
5a I
and I
5b I
( I
STAT5a I
/ I
b I
) I
. O

We O
identified O
several O
genes O
up O
- O
regulated O
by O
IL B
- I
12 I
, O
namely O
, O
MIP B
- I
1alpha I
, O
MIP B
- I
1beta I
, O
IL B
- I
1RA I
, O
and O
IFN B
regulatory I
factor I
- I
1 I
( I
IRF I
- I
1 I
) I
. O

To O
determine O
whether O
it O
is O
possible O
to O
artificially O
enhance O
the O
opening O
of O
the O
chromatin O
structure O
of O
a O
minimal B
beta I
- I
globin I
promoter I
, O
we O
placed O
a O
101bp O
, O
erythroid B
- I
specific I
DNase I
1 I
hypersensitive I
site I
- I
forming I
element I
( O
HSFE B
) O
immediately O
upstream O
of O
the O
beta B
- I
globin I
promoter I
and I
gene I
. O

Nuclear B
factor I
- I
90 I
of O
activated O
T O
- O
cells O
: O
A O
double B
- I
stranded I
RNA I
- O
binding O
protein O
and O
substrate O
for O
the O
double B
- I
stranded I
RNA I
- I
dependent I
protein I
kinase I
, O
PKR B
. O

Nuclear O
localization O
and O
formation O
of O
beta B
- I
catenin I
- I
lymphoid I
enhancer I
factor I
1 I
complexes I
are O
not O
sufficient O
for O
activation O
of O
gene O
expression O
. O

RESULTS O
: O
A O
human O
IL B
- I
5 I
promoter I
/ I
enhancer I
- I
luciferase I
gene I
construct I
, O
pIL B
- I
5 I
( I
- I
511 I
) I
Luc I
, O
was O
transcribed O
on O
activation O
of O
IL O
- O
5 O
- O
producing O
T O
- O
cell O
clones O
, O
but O
not O
IL O
- O
5 O
- O
nonproducing O
clones O
. O

RESULTS O
: O
A O
human O
IL B
- I
5 I
promoter I
/ I
enhancer I
- I
luciferase I
gene I
construct I
, O
pIL B
- I
5 I
( I
- I
511 I
) I
Luc I
, O
was O
transcribed O
on O
activation O
of O
IL O
- O
5 O
- O
producing O
T O
- O
cell O
clones O
, O
but O
not O
IL O
- O
5 O
- O
nonproducing O
clones O
. O

pIL B
- I
5 I
( I
- I
511 I
) I
Luc I
was O
transcribed O
by O
T O
- O
cell O
hybridomas O
derived O
from O
fusion O
between O
IL O
- O
5 O
- O
producing O
T O
- O
cell O
clones O
and O
an O
IL O
- O
5 O
gene O
- O
nonexpressing O
T O
- O
cell O
line O
, O
but O
not O
by O
hybridomas O
derived O
from O
IL O
- O
5 O
- O
nonproducing O
T O
- O
cell O
clones O
. O

Here O
, O
we O
show O
that O
Jagged1 B
is O
a O
Rel B
/ I
NF I
- I
kappaB I
- I
responsive I
gene I
. O

Enforced O
expression O
of O
Id3 B
, O
which O
has O
the O
capacity O
to O
inhibit O
many O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
, O
in O
human O
CD34 O
( O
+ O
) O
hematopoietic O
progenitor O
cells O
that O
have O
not O
undergone O
T B
cell I
receptor I
( I
TCR I
) I
gene I
rearrangements I
inhibits O
development O
of O
the O
transduced O
cells O
into O
TCRalpha O
beta O
and O
gamma O
delta O
cells O
in O
a O
fetal O
thymic O
organ O
culture O
( O
FTOC O
) O
. O

Enforced O
expression O
of O
Id3 B
, O
which O
has O
the O
capacity O
to O
inhibit O
many O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
, O
in O
human O
CD34 O
( O
+ O
) O
hematopoietic O
progenitor O
cells O
that O
have O
not O
undergone O
T B
cell I
receptor I
( I
TCR I
) I
gene I
rearrangements I
inhibits O
development O
of O
the O
transduced O
cells O
into O
TCRalpha O
beta O
and O
gamma O
delta O
cells O
in O
a O
fetal O
thymic O
organ O
culture O
( O
FTOC O
) O
. O

Additionally O
, O
virus O
reactivation O
in O
resting O
PBMCs O
infected O
in O
vitro O
with O
HIV O
- O
1 O
was O
found O
to O
be O
specifically O
induced O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
domain B
1 I
( O
D1 B
) O
of O
CD4 B
( O
virus B
envelope I
and I
anti I
- I
CD4 I
monoclonal I
antibodies I
) O
. O

We O
investigated O
the O
involvement O
of O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
factors I
in O
this O
phenomenon O
and O
reported O
the O
specific O
, O
time O
- O
dependent O
, O
activation O
of O
STAT1 B
protein O
starting O
at O
day O
0 O
/ O
1 O
of O
cultivation O
and O
maximally O
expressed O
at O
day O
5 O
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

Capacitance O
would O
simply O
involve O
expression O
of O
IL B
- I
12R I
beta I
1 I
and I
beta I
2 I
subunits I
, O
regulated O
by O
TCR O
, O
IL B
- I
4 I
and O
IFNs B
. O

Inhibition O
of O
T O
cell O
signaling O
by O
mitogen B
- I
activated I
protein I
kinase I
- I
targeted I
hematopoietic I
tyrosine I
phosphatase I
( O
HePTP B
) O
. O

PG490 O
can O
completely O
inhibit O
transcriptional O
activation O
at O
the O
purine B
- I
box I
/ I
ARRE I
/ I
NF I
- I
AT I
and I
NF I
- I
kappaB I
target I
DNA I
sequences I
triggered O
by O
all O
stimuli O
examined O
( O
PMA O
, O
PMA O
/ O
Iono O
, O
tumor B
necrosis I
factor I
- I
alpha I
) O
. O

Taken O
together O
, O
these O
data O
indicate O
that O
the O
unexpected O
expression O
of O
megakaryocytic B
genes I
is O
a O
specific O
property O
of O
immortalized O
cells O
that O
can O
not O
be O
explained O
only O
by O
enhanced O
expression O
of O
Spi B
- I
1 I
and I
/ I
or I
Fli I
- I
1 I
genes I
. O

Role O
of O
cellular B
tumor I
necrosis I
factor I
receptor I
- I
associated I
factors I
in O
NF B
- I
kappaB I
activation O
and O
lymphocyte O
transformation O
by O
herpesvirus O
Saimiri O
STP B
. O

However O
, O
I B
( I
kappa I
) I
B I
( I
alpha I
) I
has O
also O
been O
detected O
in O
the O
nucleus O
of O
cell O
lines O
and O
when O
overexpressed O
by O
transient O
transfection O
. O

Immunoprecipitation O
experiments O
failed O
to O
demonstrate O
an O
association O
between O
nuclear O
I B
( I
kappa I
) I
B I
( I
alpha I
) I
and O
NF B
- I
kappaB I
proteins O
. O

Similarly O
, O
IL B
- I
2 I
neither O
activates O
JNK B
nor O
increases O
AP B
- I
1 I
binding O
activity O
to O
a O
consensus O
o B
- I
tetradecanoylphorbol I
13 I
- I
acetate I
( I
TPA I
) I
response I
element I
. O

The O
activity O
of O
the O
CCAAT B
- I
box I
binding I
factor I
NF I
- I
Y I
is O
modulated O
through O
the O
regulated O
expression O
of O
its O
A B
subunit I
during O
monocyte O
to O
macrophage O
differentiation O
: O
regulation O
of O
tissue B
- I
specific I
genes I
through O
a O
ubiquitous O
transcription B
factor I
. O

Finally O
, O
oxidants O
are O
believed O
to O
promote O
intestinal O
epithelial O
cell O
apoptosis O
, O
and O
the O
B B
- I
cell I
lymphoma I
/ I
leukemia I
- I
2 I
gene I
product I
is O
believed O
to O
inhibit O
this O
phenomenon O
in O
an O
antioxidant O
- O
dependent O
manner O
. O

Members O
of O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
binding I
( I
CREB I
) I
/ I
activating I
transcription I
factor I
1 I
( I
ATF I
- I
1 I
) I
family I
of O
transcription B
factors I
bind O
three O
21 B
- I
bp I
repeats I
( O
Tax B
- I
responsive I
element I
- I
1 I
, O
or O
TRE B
- I
1 I
) O
within O
the O
viral B
promoter I
and O
are O
important O
for O
basal O
and O
Tax O
- O
mediated O
transcription O
. O

Delta O
- O
opioid O
receptors O
expressed O
by O
Jurkat O
T O
cells O
enhance O
IL B
- I
2 I
secretion O
by O
increasing O
AP B
- I
1 I
complexes I
and O
activity O
of O
the O
NF B
- I
AT I
/ I
AP I
- I
1 I
- I
binding I
promoter I
element I
. O

Reporter O
gene O
constructs O
were O
used O
to O
map O
this O
effect O
of O
deltorphin O
to O
the O
AP B
- I
1 I
- I
and I
NF I
- I
AT I
/ I
AP I
- I
1 I
- I
binding I
sites I
of O
the O
IL B
- I
2 I
promoter I
. O

We O
have O
mapped O
the O
DNase B
- I
I I
- I
hypersensitive I
( I
HS I
) I
regions I
of O
the O
human B
GATA I
- I
3 I
gene I
in O
T O
- O
cells O
and O
non O
- O
T O
- O
cells O
and O
studied O
their O
transcriptional O
activities O
. O

Among O
these O
hypersensitive B
sites I
, O
two O
transcriptional B
control I
elements I
were O
found O
, O
one O
in O
the O
first B
intron I
of O
the O
GATA B
- I
3 I
gene I
and O
the O
other O
between B
8 I
. I
3 I
and I
5 I
. I
9 I
kilobases I
5 O
' O
from O
the O
GATA B
- I
3 I
transcriptional I
initiation I
site I
. O

Two O
CAGGTG O
E O
- O
boxes O
, O
located O
at O
the O
5 B
' I
- I
and I
3 I
' I
- I
ends I
of O
the O
silencer O
, O
were O
necessary O
for O
this O
silencer O
activity O
. O

Cutting O
edge O
: O
dominant O
effect O
of O
Ile50Val B
variant I
of O
the O
human B
IL I
- I
4 I
receptor I
alpha I
- I
chain I
in O
IgE B
synthesis O
. O

Constitutive O
expression O
of O
human B
colony I
- I
stimulating I
factor I
- I
1 I
receptor I
( O
CSF B
- I
1R I
) O
confers O
long O
- O
lasting O
CSF B
- I
1 I
- O
dependent O
proliferation O
to O
mouse O
myeloid O
cell O
lines O
. O

Tumor B
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
- O
induced O
HIV O
- O
1 O
replication O
in O
OM10 O
. O
1 O
or O
Ach2 O
cells O
was O
significantly O
inhibited O
by O
non O
- O
cytotoxic O
doses O
of O
AuTG O
( O
> O
10 O
microM O
in O
OM10 O
. O
1 O
cells O
and O
> O
25 O
F O
. O
M O
in O
Ach2 O
cells O
) O
, O
while O
25 O
microM O
of O
the O
counter B
- I
anion I
thioglucose I
( O
TG B
) O
or O
gold O
compound O
containing O
divalent O
gold O
ion O
, O
HAuCl3 O
, O
had O
no O
effect O
. O

Using O
the O
wild B
- I
type I
or I
mutated I
human I
retinoic I
acid I
receptor I
alpha I
as O
a O
model O
, O
kDa O
values O
determined O
by O
classical O
competition O
binding O
assays O
using O
tritiated O
ligands O
are O
in O
agreement O
with O
those O
measured O
by O
the O
proteolytic O
assay O
. O

B O
lymphocytes O
from O
patients O
with O
chronic O
lymphocytic O
leukemia O
contain O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
1 I
and O
STAT3 B
constitutively O
phosphorylated O
on O
serine O
residues O
. O

These O
data O
indicate O
that O
the O
TRE B
- I
like I
cAMP I
- I
responsive I
DSE I
sites I
within O
the O
5 B
' I
- I
untranslated I
leader I
can O
mediate O
the O
transcriptional O
cooperativity O
between O
TNFalpha B
and O
the O
cAMP O
/ B
PKA I
pathway O
. O

In O
addition O
, O
both O
RelA B
and O
c B
- I
Rel I
, O
but O
not O
NF B
- I
kappa I
B1 I
, O
were O
shown O
to O
transactivate O
an O
ICAM B
- I
1 I
kappa I
B I
- I
reporter I
construct I
. O

Spi B
- I
1 I
/ I
PU I
. I
1 I
is O
a O
myeloid B
- I
and I
B I
- I
cell I
specific I
transcription I
factor I
which O
is O
also O
involved O
in O
Friend O
virus O
- O
induced O
murine O
erythroleukemia O
. O

The O
class B
II I
trans I
- I
activator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multi I
- I
functional I
domain I
protein I
which O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

The O
tax B
protein I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
mediates O
the O
transactivation O
of O
the O
c B
- I
sis I
/ I
platelet I
- I
derived I
growth I
factor I
- I
B I
promoter I
through O
interactions O
with O
the O
zinc B
finger I
transcription I
factors I
Sp1 B
and O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

In O
the O
present O
work O
, O
we O
have O
investigated O
the O
mechanism O
( O
s O
) O
whereby O
Tax B
transactivates O
the O
c B
- I
sis I
/ I
PDGF I
- I
B I
proto I
- I
oncogene I
. O

The O
CAML B
( I
calcium I
- I
modulator I
and I
cyclophilin I
ligand I
) I
protein I
is O
a O
coinducer O
of O
NF B
- I
AT I
activation O
when O
overexpressed O
in O
Jurkat O
T O
cells O
. O

Proteins O
of O
the O
ATF O
/ O
CREB B
class O
of O
transcription B
factors I
stimulate O
gene O
expression O
of O
several O
cell B
growth I
- I
related I
genes I
through O
protein B
kinase I
A I
- I
related I
cAMP I
response I
elements I
. O

Nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
/ I
Rel I
transcription I
factors I
may O
be O
involved O
in O
atherosclerosis O
, O
as O
is O
suggested O
by O
the O
presence O
of O
activated O
NF B
- I
kappa I
B I
in O
human O
atherosclerotic O
lesions O
. O

The O
immediate O
- O
early O
gene O
product O
Egr B
- I
1 I
regulates O
the O
human B
interleukin I
- I
2 I
receptor I
beta I
- I
chain I
promoter I
through O
noncanonical B
Egr I
and I
Sp1 I
binding I
sites I
. O

In O
this O
study O
, O
we O
show O
that O
HNF B
- I
3alpha I
, I
- I
3beta I
, I
- I
3gamma I
, I
- I
4gamma I
, I
and I
- I
6 I
are O
expressed O
in O
pancreatic O
beta O
- O
cells O
. O

Molecular O
cloning O
of O
SLAP B
- I
130 I
, O
an O
SLP B
- I
76 I
- I
associated I
substrate I
of O
the O
T B
cell I
antigen I
receptor I
- I
stimulated I
protein I
tyrosine I
kinases I
. O

In O
fact O
, O
mAb B
L243 I
but O
not O
the O
staphylococcal B
superantigens I
, O
staphylococcal B
exotoxin I
toxic I
shock I
syndrome I
toxin I
- I
I I
or O
staphylococcal B
enterotoxin I
B I
, O
regulate O
the O
NF B
- I
kappa I
B I
binding O
activity O
. O

Regulation O
of O
inosine B
- I
5 I
' I
- I
monophosphate I
dehydrogenase I
type I
II I
gene O
expression O
in O
human O
T O
cells O
. O

NAC O
had O
no O
effect O
on O
the O
half O
- O
life O
of O
E B
- I
selectin I
or I
VCAM I
- I
1 I
mRNA I
. O

Both O
signal O
cascades O
contribute O
to O
the O
induction O
of O
the O
interleukin B
2 I
( I
IL I
- I
2 I
) I
gene I
during O
T O
- O
cell O
activation O
. O

IFN B
- I
alpha I
/ I
beta I
specifically O
induced O
tyrosine O
phosphorylation O
and O
translocation O
into O
nucleus O
of O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
2 I
protein I
in O
the O
T O
cell O
clones O
. O

Acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
associated O
with O
reciprocal O
chromosomal O
translocations O
involving O
the O
retinoic B
acid I
receptor I
alpha I
( I
RARalpha I
) I
locus I
on O
chromosome B
17 I
. O

To O
better O
understand O
the O
AP B
- I
1 I
- O
dependent O
luciferase B
expression O
in O
Jurkat O
T O
cells O
, O
we O
tested O
two O
specific O
inhibitors O
of O
serine B
/ I
threonine I
phosphatases I
- I
1 I
and I
- I
2A I
: O
okadaic O
acid O
and O
calyculin O
A O
. O

Human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Tat I
, O
an O
early O
regulatory B
protein I
that O
is O
critical O
for O
viral O
gene O
expression O
and O
replication O
, O
transactivates O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
via O
its O
binding O
to O
the O
transactivation B
response I
element I
( O
TAR B
) O
and O
, O
along O
with O
other O
cellular O
factors O
, O
increases O
viral O
transcription O
initiation O
and O
elongation O
. O

In O
this O
study O
, O
a O
combined O
pharmacologic O
and O
genetic O
strategy O
using O
two O
PKC B
( O
NF B
- I
kappa I
B I
) O
inhibitors O
, O
pentoxifylline O
( O
PTX O
) O
and O
Go O
- O
6976 O
, O
and O
a O
stably O
expressed O
anti B
- I
Tat I
single I
- I
chain I
intracellular I
antibody I
( O
sFv B
intrabody I
) O
was O
employed O
to O
obtain O
cooperative O
inhibition O
of O
both O
HIV O
- O
1 O
LTR B
- O
driven O
gene O
expression O
and O
HIV O
- O
1 O
replication O
. O

Inducible O
expression O
and O
phosphorylation O
of O
coactivator B
BOB I
. I
1 I
/ I
OBF I
. I
1 I
in O
T O
cells O
[ O
see O
comments O
] O

Patients O
with O
one O
type O
of O
major B
histocompatibility I
complex I
class I
II I
combined O
immunodeficiency O
have O
mutations O
in O
a O
gene O
termed O
class B
II I
transactivator I
( O
CIITA B
) O
, O
which O
coordinately O
controls O
the O
transcription O
of O
the O
three O
major O
human B
class I
II I
genes I
, O
HLA B
- I
DR I
, I
- I
DQ I
, I
and I
- I
DP I
. O

Triggering O
of O
HLA B
class I
II I
antigens I
by O
the O
anti B
- I
HLA I
- I
DR I
monoclonal I
antibody I
( I
mAb I
) I
L243 I
significantly O
( O
P O
< O
0 O
. O
05 O
) O
and O
differentially O
enhanced O
the O
release O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
by O
the O
non O
- O
Hodgkin O
' O
s O
lymphoma O
cells O
Ri O
- O
I O
, O
Ci O
- O
I O
, O
and O
Sc O
- O
I O
, O
which O
are O
at O
a O
distinct O
stage O
of O
B O
- O
cell O
differentiation O
, O
and O
by O
the O
more O
mature O
Burkitt O
lymphoma O
cell O
Raji O
; O
in O
contrast O
, O
it O
did O
not O
induce O
TNF B
- I

The O
predictive B
protein I
- I
coding I
region I
of O
RP1 B
had O
a O
significant O
homology O
to O
members O
of O
the O
recently O
found O
adenomatous B
polyposis I
coli I
( I
APC I
) I
protein I
- I
binding I
EB1 I
gene I
family I
, O
which O
codes O
for O
yet O
unknown O
protein O
( O
s O
) O
. O

We O
have O
generated O
transgenic O
mice O
that O
express O
a O
catalytically B
inactive I
form I
of O
Ca2 B
+ I
/ I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
specifically O
in O
thymic O
T O
cells O
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter O
deletion O
analyses O
suggested O
a O
role O
for O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
- I
beta I
( I
C I
/ I
EBP I
- I
beta I
) I
binding I
site I
between O
- B
2010 I
and I
- I
1954 I
in O
regulating O
transcription O
of O
collagenase B
- I
1 I
in O
monocytic O
cells O
. O

Signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
( O
STAT3 B
) O
is O
constitutively O
activated O
in O
normal O
, O
self O
- O
renewing O
B O
- O
1 O
cells O
but O
only O
inducibly O
expressed O
in O
conventional O
B O
lymphocytes O
[ O
see O
comments O
] O

Cytokine B
and O
growth B
factor I
receptor I
engagement O
leads O
to O
the O
rapid O
phosphorylation O
and O
activation O
of O
latent O
, O
cytosolic B
signal I
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
proteins I
, O
which O
then O
translocate O
to O
the O
nucleus O
where O
they O
regulate O
transcriptional O
events O
from O
specific B
promoter I
sequences I
. O

The O
two O
AP B
- I
1 I
sites I
bound O
c B
- I
Fos I
/ I
c I
- I
Jun I
heterodimers I
in O
both O
unstimulated O
and O
LPS O
- O
stimulated O
cells O
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human B
immunodeficiency I
virus I
Tat I
, O
human B
papillomavirus I
E6 I
, O
and O
Bicoid B
, O
or O
with O
the O
M7 B
( I
amino I
acids I
29CP I
- I
AS I
) I
Tax1 I
mutant I
. O

Impaired O
induction O
of O
c B
- I
fos I
/ I
c I
- I
jun I
genes I
and O
of O
transcriptional B
regulatory I
proteins I
binding O
distinct O
c B
- I
fos I
/ I
c I
- I
jun I
promoter I
elements I
in O
activated O
human O
T O
cells O
during O
aging O
. O

Impaired O
induction O
of O
c B
- I
fos I
/ I
c I
- I
jun I
genes I
and O
of O
transcriptional B
regulatory I
proteins I
binding O
distinct O
c B
- I
fos I
/ I
c I
- I
jun I
promoter I
elements I
in O
activated O
human O
T O
cells O
during O
aging O
. O

In O
addition O
, O
RNase B
protection O
assays O
revealed O
that O
anti O
- O
CD3 O
/ O
PMA O
- O
stimulated O
T O
cells O
from O
a O
substantial O
proportion O
of O
elderly O
subjects O
exhibited O
decreased O
levels O
of O
c B
- I
fos I
and I
/ I
or I
c I
- I
jun I
mRNA I
compared O
to O
T O
cells O
from O
young O
subjects O
. O

IL O
- O
4 O
treatment O
rapidly O
induced O
tyrosine O
phosphorylation O
of O
insulin B
receptor I
substrate I
( I
IRS I
) I
- I
1 I
and O
IRS B
- I
2 I
in O
1D4 O
but O
not O
in O
E1C3 O
cells O
. O

The O
negative B
regulatory I
element I
( O
NRE B
) O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
core I
promoter I
contains O
three O
subregions O
which O
act O
synergistically O
to O
suppress O
core O
promoter O
activity O
. O

Residues O
432 O
, O
435 O
, O
437 O
, O
438 O
, O
and O
440 O
( O
position B
P1 I
, I
P4 I
, I
P6 I
, I
P7 I
, I
and I
P9 I
) O
contributed O
to O
DQ2 B
binding O
, O
whereas O
residues O
431 O
, O
433 O
, O
434 O
, O
and O
436 O
( O
positions B
P I
1 I
, I
P2 I
, I
P3 I
, I
and I
P5 I
) O
contributed O
to O
TCR B
contact O
. O

Residues O
432 O
, O
435 O
, O
437 O
, O
438 O
, O
and O
440 O
( O
position B
P1 I
, I
P4 I
, I
P6 I
, I
P7 I
, I
and I
P9 I
) O
contributed O
to O
DQ2 B
binding O
, O
whereas O
residues O
431 O
, O
433 O
, O
434 O
, O
and O
436 O
( O
positions B
P I
1 I
, I
P2 I
, I
P3 I
, I
and I
P5 I
) O
contributed O
to O
TCR B
contact O
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
proteins I
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV B
glycoprotein I
E I
( O
gE B
) O
, O
encoded O
by O
ORF B
68 I
and O
the O
VZV B
product I
of O
ORF B
62 I
, O
an O
immediate B
- I
early I
major I
tegument I
protein I
( O
IE62 B
) O
. O

EGF O
treatment O
induced O
IgM B
production O
in O
cells O
transfected O
with O
an O
intact O
gp130 B
cytoplasmic I
tail I
, O
but O
not O
in O
untransfected O
cells O
or O
cells O
transfected O
with O
a O
cytoplasmic B
tail I
lacking O
all O
four O
signal B
transducers I
and I
activators I
of I
transcription I
( I
Stat I
) I
binding I
sites I
. O

The O
transcriptional B
regulatory I
elements I
of O
many O
inducible B
T I
- I
cell I
genes I
contain O
adjacent O
or O
overlapping B
binding I
sites I
for O
the O
Ets B
and I
NF I
- I
kappaB I
/ I
NFAT I
families I
of O
transcription B
factors I
. O

Stimulation O
with O
either O
PAF B
or O
FMLP B
resulted O
in O
equivalent O
phosphorylation O
and O
activation O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPk I
) I
homologue I
38 B
- I
kD I
murine I
MAP I
kinase I
homologous O
to O
HOG B
- I
1 I
( I
p38 I
) I
MAPk I
. O

The O
DNA B
- I
binding I
domain I
( O
amino B
acids I
421 I
- I
486 I
) O
is O
completely O
conserved O
among O
human B
, I
squirrel I
monkey I
, I
owl I
monkey I
, I
and I
cotton I
- I
top I
tamarin I
receptors I
. O

The O
gamma B
( I
c I
) I
subunit I
can O
be O
employed O
in O
receptor B
complexes I
for O
IL B
- I
2 I
, I
- I
4 I
, I
- I
7 I
, I
- I
9 I
, I
and I
- I
15 I
, O
and O
the O
multiple O
signaling O
defects O
that O
would O
result O
from O
a O
defective O
gamma B
( I
c I
) I
chain I
in O
these O
receptors O
are O
proposed O
to O
cause O
the O
severe O
phenotype O
of O
X O
- O
SCID O
patients O
. O

The O
low O
frequency O
with O
which O
these O
Ig O
- O
expressing O
hybrids O
are O
recovered O
, O
along O
with O
the O
fact O
that O
cell O
fusions O
can O
lead O
to O
chromosome O
loss O
, O
led O
us O
to O
propose O
that O
this O
rare O
phenotype O
was O
due O
to O
loss O
of O
a O
T B
- I
cell I
- I
derived I
chromosome I
encoding I
a I
factor I
or O
factors O
with O
gene O
silencing O
activity O
. O

In O
this O
study O
, O
a O
series O
of O
Burkitt O
' O
s O
lymphoma O
( O
BL O
) O
cell O
lines O
were O
assayed O
for O
their O
expression O
of O
tissue B
inhibitor I
of I
metalloproteinases I
( I
TIMP I
) I
- I
1 I
. O

To O
investigate O
in O
vivo O
regulatory O
mechanisms O
that O
control O
the O
population O
of O
type O
2 O
T O
cells O
and O
disease O
susceptibility O
, O
we O
have O
created O
lines O
of O
transgenic O
mice O
in O
which O
expression O
of O
a O
chimeric B
cytokine I
receptor I
( O
the O
mouse B
interleukin I
2 I
receptor I
beta I
chain I
[ I
IL I
- I
2Rbeta I
] I
extracellular I
domain I
fused O
to O
the O
cytoplasmic B
tail I
of O
IL B
- I
4Ralpha I
) O
is O
targeted O
to O
the O
T O
lymphoid O
lineage O
using O
the O
proximal B
lck I
promoter I
. O

In O
particular O
, O
TRAF6 B
interacted O
with O
membrane B
- I
proximal I
determinants I
distinct O
from O
those O
binding O
TRAFs B
1 I
, I
2 I
, I
3 I
, I
and I
5 I
. O

The O
molecular O
mechanisms O
by O
which O
IL B
- I
4 I
induces O
expression O
of O
the O
IL B
- I
4 I
gene I
are O
not O
known O
, O
although O
the O
IL B
- I
4 I
- I
activated I
transcription I
factor I
signal I
transducer I
and I
activator I
of I
transcription I
6 I
( O
Stat6 B
) O
is O
required O
for O
this O
effect O
. O

The O
triptolide O
- O
induced O
apoptosis O
is O
accompanied O
by O
increase O
of O
DEVD O
- O
cleavable O
caspases B
activity O
and O
degradation O
of O
caspase B
substrate I
poly I
( I
ADP I
- I
ribose I
) I
polymerase I
( O
PARP B
) O
. O

Further O
, O
we O
show O
that O
inhibitory O
NLS B
peptide O
interacts O
in O
vitro O
with O
a O
cytoplasmic B
NLS I
receptor I
complex I
comprised O
of O
the O
Rch1 B
/ I
importin I
( I
karyopherin I
) I
- I
beta I
heterodimer I
expressed O
in O
Jurkat O
T O
cells O
. O

A O
novel O
member O
of O
the O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
family I
, O
designated O
TRAMP B
, O
has O
been O
identified O
. O

The O
gene O
encodes O
an O
85 B
- I
kDa I
protein I
, O
designated O
BASH B
( O
B B
cell I
adaptor I
containing I
SH2 I
domain I
) O
, O
that O
contains O
N B
- I
terminal I
acidic I
domains I
with O
SH2 B
domain I
- I
binding I
phosphotyrosine I
- I
based I
motifs I
, O
a O
proline B
- I
rich I
domain I
, O
and O
a O
C B
- I
terminal I
SH2 I
domain I
. O

Since O
the O
AES B
proteins I
are O
part O
of O
a O
set O
of O
transcriptional O
repressors O
encoded O
by O
the O
Enhancer B
of I
split I
[ I
E I
( I
spl I
) I
] I
genes I
, O
and O
since O
these O
repressors O
are O
activated O
to O
suppress O
cell O
differentiation O
in O
response O
to O
Notch B
receptors I
signalling O
, O
the O
AES O
peptides O
may O
represent O
a O
novel O
class O
of O
self B
- I
antigens I
that O
deserve O
further O
consideration O
as O
tumor B
Ag I
in O
epithelial O
cancers O
. O

The O
action O
of O
adenoviral B
E1A I
oncoprotein I
on O
host B
immune I
- I
response I
genes I
has O
been O
attributed O
to O
interaction O
with O
p300 B
/ I
CBP I
- I
type I
transcriptional I
coactivators I
in O
competition O
with O
endogenous B
transcription I
factors I
such O
as O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
proteins I
. O

Recently O
, O
a O
technique O
of O
clonal O
analysis O
has O
been O
devised O
that O
takes O
advantage O
of O
a O
highly O
polymorphic O
short B
tandem I
repeat I
within O
the O
X B
- I
linked I
human I
androgen I
receptor I
( I
AR I
) I
gene I
, O
resulting O
in O
a O
heterozygosity O
rate O
approaching O
90 O
% O
. O

We O
have O
generated O
antibodies O
that O
specifically O
immunoprecipitated O
the O
in B
- I
vitro I
- I
translated I
20 I
- I
kDa I
protein I
. O

The O
nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappaB I
) I
family I
of O
transcription B
factors I
regulates O
genes O
involved O
in O
inflammation O
, O
cell O
proliferation O
, O
and O
cell O
differentiation O
. O

The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
essential O
for O
the O
expression O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class I
II I
antigens I
. O

Electrophoretic O
mobility O
shift O
assays O
( O
EMSAs O
) O
demonstrated O
that O
the O
- O
300 O
region O
of O
the O
IL B
- I
1beta I
promoter O
, O
which O
contains O
a O
nuclear B
factor I
- I
kappaB I
( I
NF I
- I
kappaB I
) I
binding I
site I
, O
contained O
a O
functional B
RBP I
binding I
site I
. O

Ligation O
of O
CD3 B
also O
induces O
the O
tyrosine O
phosphorylation O
of O
HS1 B
, O
a O
75 B
- I
kDa I
hematopoietic I
cell I
- I
specific I
intracellular I
signaling I
protein I
of O
unknown O
function O
. O

In O
addition O
, O
Northern O
blot O
analysis O
of O
cord O
and O
adult O
samples O
revealed O
similar O
maximal O
increases O
in O
c B
- I
fos I
( O
99 O
+ O
/ O
- O
15 O
and O
126 O
+ O
/ O
- O
11 O
% O
, O
p O
= O
0 O
. O
0126 O
) O
and O
c B
- I
jun I
( I
123 I
+ I
/ I
- I
9 I
and I
185 I
+ I
/ I
- I
38 I
% I
, I
p I
= I
0 I
. I
0291 I
) I
mRNA I
expression O
, O
respectively O
, O
as O
early O
as O
15 O
min O
post O
- O
alphaCD3 B
stimulation O
. O

A O
regulatory B
element I
in O
the O
CD95 B
( I
APO I
- I
1 I
/ I
Fas I
) I
ligand I
promoter I
is O
essential O
for O
responsiveness O
to O
TCR B
- O
mediated O
activation O
. O

Activation O
of O
the O
CD4 B
promoter I
occurs O
in O
the O
presence O
of O
the O
viral O
DNA O
polymerase O
inhibitor O
phosphonoformic O
acid O
, O
which O
limits O
expression O
to O
the O
immediate B
- I
early I
and I
early I
classes I
of I
viral I
genes I
. O

This O
study O
shows O
that O
expression O
of O
LMP1 B
activates O
transcription O
from O
p50 B
/ I
p65 I
- I
and I
c I
- I
Rel I
- I
responsive I
promoters I
, O
and O
that O
this O
activity O
can O
be O
completely O
inhibited O
by O
expression O
of O
a O
dominant O
inhibitory B
IkappaB I
mutant I
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

The O
ability O
of O
mutants O
to O
activate O
a O
reporter O
gene O
under O
the O
control O
of O
MHC B
class I
II I
conserved O
W B
- I
X I
- I
Y I
or I
X I
- I
Y I
regulatory I
elements I
was O
determined O
. O

Two O
mutants O
displayed O
differential O
activity O
between O
the O
two O
promoters B
, O
activating O
transcription O
with O
the O
W B
- I
X I
- I
Y I
but I
not I
the I
X I
- I
Y I
elements I
. O

Activation O
of O
E2F B
- O
mediated O
transcription O
by O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
Tax I
protein I
in O
a O
p16 O
( O
INK4A O
) O
- O
negative O
T O
- O
cell O
line O
. O

Differential O
responsiveness O
of O
the O
IL B
- I
5 I
and I
IL I
- I
4 I
genes I
to O
transcription B
factor I
GATA I
- I
3 I
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
bis O
[ O
4 O
- O
[ O
2 O
, O
4 O
- O
dioxo O
- O
5 O
- O
thiazolidinyl O
) O
methyl O
] O
phenyl O
] O
methane O
( O
YM O
- O
268 O
) O
, O
a O
thiazolidinedione O
derivative O
, O
on O
glucose O
uptake O
, O
adipocyte O
differentiation O
through O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
, O
and O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
activity O
in O
cultured O
cells O
. O

Molecular O
and O
cellular O
analysis O
of O
human O
immunodeficiency O
virus O
- O
induced O
apoptosis O
in O
lymphoblastoid B
T I
- I
cell I
- I
line I
- I
expressing I
wild I
- I
type I
and I
mutated I
CD4 I
receptors I
. O

Previously O
, O
we O
demonstrated O
that O
granulocyte B
colony I
- I
stimulating I
factor I
( I
G I
- I
CSF I
) I
receptor I
mRNA I
was O
undetectable O
and O
granulocyte O
maturation O
blocked O
in O
CCAAT B
enhancer I
binding I
protein I
alpha I
( O
C B
/ I
EBPalpha I
) O
- O
deficient O
mice O
. O

To O
differentiate O
whether O
the O
RA O
effect O
was O
mediated O
by O
RA B
receptors I
alpha I
, I
beta I
, I
and I
gamma I
, O
the O
expression O
of O
the O
retinoic B
acid I
receptors I
( O
RAR B
) O
was O
examined O
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
. O

Here O
we O
investigated O
the O
impact O
of O
retinoid B
X I
receptor I
( O
RXR B
) O
, O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
of O
the O
c B
- I
erbA I
/ I
thyroid I
hormone I
( I
T3 I
) I
receptor I
( O
c B
- I
erbA I
/ I
TR I
) O
on O
growth O
and O
differentiation O
of O
erythroid O
cells O
using O
an O
in O
vitro O
culture O
system O
of O
stem O
cell O
factor O
- O
dependent O
erythroid O
progenitors O
. O

Data O
obtained O
by O
electrophoretic O
mobility O
shift O
assay O
suggested O
that O
the O
activated B
Stat I
- I
3 I
protein I
associates O
with O
the O
human B
serum I
- I
inducible I
element I
( I
hSIE I
) I
DNA I
- I
probe I
derived O
from O
the O
interferon B
- I
gamma I
activated I
site I
( O
GAS B
) O
in O
the O
c B
- I
fos I
promoter I
, O
a O
common O
DNA O
sequence O
for O
Stat B
protein I
binding O
. O

Macrophages O
in O
human O
atheroma O
contain O
PPARgamma B
: O
differentiation B
- I
dependent I
peroxisomal I
proliferator I
- I
activated I
receptor I
gamma I
( O
PPARgamma B
) O
expression O
and O
reduction O
of O
MMP B
- I
9 I
activity O
through O
PPARgamma B
activation O
in O
mononuclear O
phagocytes O
in O
vitro O
. O

We O
conclude O
that O
the O
t B
( I
10 I
; I
11 I
) I
( I
p13 I
; I
q14 I
) I
indicates O
CALM B
and I
MLL I
rearrangements I
in O
morphologically O
distinct O
subsets O
of O
acute O
leukemia O
and O
may O
be O
associated O
with O
a O
poor O
prognosis O
. O

The O
concentration O
of O
c B
- I
fos I
, I
c I
- I
jun I
, I
c I
- I
myc I
, I
junB I
, I
and I
fra I
- I
1 I
mRNAs I
was O
increased O
in O
activated O
peripheral O
blood O
lymphocytes O
incubated O
with O
ciprofloxacin O
compared O
to O
that O
in O
untreated O
controls O
. O

In O
this O
study O
we O
analyzed O
the O
T B
cell I
receptor I
( I
TcR I
) I
delta I
transcripts I
expressed O
by O
CD3 O
- O
CD16 O
+ O
cells O
and O
we O
investigated O
whether O
these O
cells O
expressed O
the O
hGATA B
- I
3 I
T I
cell I
transcription I
factor I
and O
the O
recombination B
- I
activating I
gene I
( I
RAG I
) I
- I
1 I
. O

In O
this O
study O
we O
analyzed O
the O
T B
cell I
receptor I
( I
TcR I
) I
delta I
transcripts I
expressed O
by O
CD3 O
- O
CD16 O
+ O
cells O
and O
we O
investigated O
whether O
these O
cells O
expressed O
the O
hGATA B
- I
3 I
T I
cell I
transcription I
factor I
and O
the O
recombination B
- I
activating I
gene I
( I
RAG I
) I
- I
1 I
. O

Jurkat O
cells O
were O
transfected O
with O
plasmids B
containing O
either O
the O
intact O
IL B
- I
2 I
promoter I
or O
its O
AP B
- I
1 I
, I
NF I
- I
AT I
, I
and I
NF I
- I
kB I
motifs I
. O

Additionally O
, O
Nef O
expressing O
cells O
were O
transiently O
transfected O
with O
a O
plasmid O
in O
which O
HIV B
- I
1 I
AP I
- I
1 I
DNA I
recognition I
sequences I
were O
cloned O
downstream O
of O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
gene O
. O

Cell O
- O
type O
- O
specific O
transactivation O
of O
the O
parathyroid B
hormone I
- I
related I
protein I
gene I
promoter I
by O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
tax I
and O
HTLV B
- I
II I
tax I
proteins I
. O

The O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
and I
HTLV I
- I
II I
Tax I
proteins I
are O
potent O
transactivators B
of O
viral O
and O
cellular O
gene O
expression O
. O

Long O
- O
lasting O
IL B
- I
2 I
receptivity O
is O
associated O
with O
high O
- O
level O
expression O
of O
the O
inducible O
IL B
- I
2 I
receptor I
alpha I
chain I
( I
IL I
- I
2R I
alpha I
) I
gene I
that O
is O
regulated O
at O
both O
transcriptional O
and O
posttranscriptional O
levels O
. O

A O
cell B
- I
type I
- I
independent I
lipopolysaccharide I
( I
LPS I
) I
- I
responsive I
enhancer I
element I
located O
between O
- B
3757 I
and I
- I
2729 I
bp I
upstream I
from O
the O
transcription B
start I
site I
( O
cap B
site I
) O
consisted O
of O
at O
least O
six O
discrete O
subregions O
which O
were O
essential O
to O
the O
maximal O
induction O
by O
LPS O
in O
transfected O
monocytes O
. O

We O
find O
that O
a O
short O
enhancer O
element O
containing O
the O
NF B
- I
kappa I
B I
binding I
site I
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
gene I
( O
IL B
- I
2R I
alpha I
) O
is O
preferentially O
activated O
in O
T O
cells O
. O

All O
groups O
contain O
cysteine B
- I
and I
histidine I
- I
rich I
putative I
zinc I
finger I
domains I
and O
a O
serine B
- I
phenylalanine I
` I
` I
SFS I
' I
' I
domain I
similar O
to O
part O
of O
the O
large O
subunit O
of O
eukaryotic B
RNA I
polymerase I
II I
. O

All O
groups O
contain O
cysteine B
- I
and I
histidine I
- I
rich I
putative I
zinc I
finger I
domains I
and O
a O
serine B
- I
phenylalanine I
` I
` I
SFS I
' I
' I
domain I
similar O
to O
part O
of O
the O
large O
subunit O
of O
eukaryotic B
RNA I
polymerase I
II I
. O

A O
microB B
binding I
protein I
is O
encoded O
by O
the O
PU B
. I
1 I
/ I
Spi I
- I
1 I
proto I
- I
oncogene I
. O

Protease O
treatment O
of O
nuclear O
extracts O
distinguishes O
between O
class B
II I
MHC I
X1 I
box I
DNA I
- I
binding I
proteins I
in O
wild O
- O
type O
and O
class O
II O
- O
deficient O
B O
cells O
. O

OBJECTIVE O
: O
To O
examine O
the O
inter O
- O
relationship O
between O
HIV O
- O
1 O
infection O
and O
the O
cell O
surface O
receptors O
for O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
an O
immunoregulatory O
cytokine O
that O
can O
enhance O
HIV O
- O
1 O
replication O
. O

Target O
antigens O
defined O
by O
autoantibodies B
in O
IDDM O
include O
insulin O
, O
a O
putative O
glycolipid O
that O
reacts O
with O
islet B
cell I
antibodies I
, O
and O
a O
64 B
, I
000 I
- I
M I
( I
r I
) I
protein I
recently O
identified O
as O
glutamic B
acid I
decarboxylase I
. O

Studies O
with O
5 B
' I
deletion I
CD20 I
promoter I
- I
CAT I
constructs I
have O
previously O
revealed O
two O
regions O
of O
the O
promoter B
between O
bases O
- O
186 O
and O
- O
280 O
and O
between O
bases O
- O
280 O
and O
- O
454 O
which O
contained O
positive B
regulatory I
elements I
. O

Early B
B I
- I
cell I
factor I
( O
EBF B
) O
was O
identified O
previously O
as O
a O
tissue O
- O
specific O
and O
differentiation O
stage O
- O
specific O
DNA B
- I
binding I
protein I
that O
participates O
in O
the O
regulation O
of O
the O
pre B
- I
B I
and I
B I
lymphocyte I
- I
specific I
mb I
- I
1 I
gene I
. O

Deletions O
delineated O
a O
carboxy B
- I
terminal I
dimerization I
region I
containing O
two O
repeats O
of O
15 O
amino O
acids O
that O
show O
similarity O
with O
the O
dimerization B
domains I
of O
basic B
- I
helix I
- I
loop I
- I
helix I
proteins I
. O

The O
inhibition O
of O
c B
- I
fos I
and O
c O
- O
jun O
expression O
by O
IL B
- I
4 I
in O
LPS O
- O
treated O
cells O
was O
shown O
to O
be O
due O
to O
a O
lower O
transcription O
rate O
of O
the O
c B
- I
fos I
and I
c I
- I
jun I
genes I
. O

The O
expression O
of O
c B
- I
fos I
, I
c I
- I
jun I
and I
jun I
B I
proto I
- I
oncogenes I
was O
studied O
in O
phytohemagglutinin O
( O
PHA O
) O
activated O
peripheral O
blood O
lymphocytes O
( O
PBL O
) O
from O
young O
and O
aged O
humans O
. O

The O
helix B
- I
loop I
- I
helix I
( I
HLH I
) I
proteins I
are O
a O
family O
of O
transcription B
factors I
that O
include O
proteins O
critical O
to O
differentiation O
and O
development O
in O
species O
ranging O
from O
plants O
to O
mammals O
. O

Regulation O
of O
replicative O
functions O
in O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
genome I
is O
mediated O
through O
activation O
of O
a O
virally B
encoded I
transcription I
factor I
, O
Z B
( O
BZLF1 B
) O
. O

A O
novel B
T I
cell I
- I
specific I
negative I
regulatory I
element I
( O
NRE B
) O
composed O
of O
two O
protein O
- O
binding O
sites O
were O
mapped O
in O
the O
5 O
' O
flanking O
region O
of O
the O
IL B
- I
4 I
gene I
: O
- O
311CTCCCTTCT O
- O
303 O
( O
NRE B
- I
I I
) O
and O
- O
288CTTTTTGCTT O
- O
TGC O
- O
300 O
( O
NRE B
- I
II I
) O
. O

Differential O
binding O
affinities O
were O
also O
obtained O
with O
p50 B
- I
and I
c I
- I
Rel I
- I
selected I
sequences I
. O

Within O
this O
region O
, O
single O
AP B
- I
2 I
- I
and I
AP I
- I
1 I
- I
like I
consensus I
sequences I
were O
noted O
. O

Mice O
transgenic O
for O
the O
human B
T I
cell I
leukemia I
virus I
( I
HTLV I
- I
I I
) I
Tax I
gene I
develop O
fibroblastic O
tumors O
that O
express O
NF B
- I
kappa I
B I
- I
inducible I
early I
genes I
. O

Mice O
transgenic O
for O
the O
human B
T I
cell I
leukemia I
virus I
( I
HTLV I
- I
I I
) I
Tax I
gene I
develop O
fibroblastic O
tumors O
that O
express O
NF B
- I
kappa I
B I
- I
inducible I
early I
genes I
. O

Inducibility O
of O
endogenous O
IFN B
- I
beta I
and I
IFN I
- I
alpha I
RNA I
was O
also O
increased O
in O
PLB O
- O
IIIB O
cells O
. O

Chloramphenicol B
acetyl I
transferase I
( O
CAT B
) O
assays O
using O
the O
HIV B
- I
1 I
( I
- I
139 I
) I
long I
terminal I
repeat I
- I
CAT I
construct I
showed O
no O
PMA O
induction O
of O
CAT B
activity O
in O
these O
subclones O
( O
unlike O
the O
parental O
line O
and O
other O
subclones O
) O
. O

Although O
it O
has O
been O
previously O
shown O
that O
the O
IL B
- I
6 I
kappa I
B I
motif I
functions O
as O
a O
potent O
IL B
- I
1 I
/ I
tumor I
necrosis I
factor I
- I
responsive I
element I
in O
nonlymphoid O
cells O
, O
its O
activity O
was O
found O
to O
be O
repressed O
in O
lymphoid O
cells O
such O
as O
a O
Jurkat O
T O
- O
cell O
line O
. O

This O
protein B
- I
DNA I
complex I
comigrated O
with O
the O
complex O
obtained O
with O
the O
purified B
human I
p65 I
NF I
- I
kappa I
B I
subunit I
and O
binding O
was O
inhibited O
by O
I B
kappa I
B I
- I
alpha I
and O
- O
beta O
proteins O
. O

The O
v B
- I
erbA I
oncoprotein I
represents O
a O
retrovirus O
- O
transduced O
oncogenic O
version O
of O
the O
thyroid B
hormone I
( I
T3 I
/ I
T4 I
) I
receptor I
c B
- I
erbA I
( I
type I
alpha I
) I
. O

The O
conversion O
of O
the O
TCEd B
to O
a O
' B
perfect I
' I
NF I
- I
kB I
binding I
site I
leads O
to O
a O
tighter O
binding O
of O
NF B
- I
kB I
to O
TCEd B
DNA I
and O
, O
as O
a O
functional O
consequence O
, O
to O
the O
activity O
of O
the O
' B
converted I
' I
TCEd I
motifs I
in O
HeLa O
cells O
. O

These O
findings O
suggest O
that O
expression O
of O
the O
1 B
, I
25 I
- I
( I
OH I
) I
2D3 I
receptor I
in O
lymphocytes O
is O
triggered O
by O
distinct O
and O
contingent O
signals O
, O
and O
that O
the O
protein O
and O
the O
mRNA B
encoding O
it O
are O
identical O
to O
the O
classical B
vitamin I
D I
receptor I
. O

Previous O
studies O
have O
shown O
that O
treatment O
of O
human O
myeloid O
leukemia O
cells O
with O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
is O
associated O
with O
induction O
of O
monocytic O
differentiation O
and O
expression O
of O
the O
c B
- I
jun I
and I
c I
- I
fos I
early I
response I
genes I
. O

The O
nuclear O
extracts O
from O
resting O
and O
induced O
ML O
- O
1 O
cells O
contain O
proteins O
binding O
specifically O
to O
the O
AP B
- I
1 I
, I
AP I
- I
2 I
, I
and I
NF I
kappa I
B I
sequence I
located O
within O
the O
TNF B
promoter I
. O

The O
murine B
and I
human I
factors I
are O
abundantly O
expressed O
in O
a O
variety O
of O
human O
and O
murine O
T O
- O
cell O
lines O
and O
can O
activate O
transcription O
through O
a O
tissue B
- I
specific I
GATA I
- I
binding I
site I
identified O
within O
the O
human B
T I
- I
cell I
receptor I
delta I
gene I
enhancer I
. O

Expression O
of O
c B
- I
jun I
, I
jun I
B I
and I
jun I
D I
proto I
- I
oncogenes I
in O
human O
peripheral O
- O
blood O
granulocytes O
. O

We O
have O
found O
that O
purified O
human O
peripheral O
- O
blood O
granulocytes O
express O
constitutively O
significant O
levels O
of O
proto B
- I
oncogenes I
c B
- I
jun I
, I
jun I
B I
and I
jun I
D I
mRNA I
. O

The O
29 B
- I
kDa I
proteins I
phosphorylated O
in O
thrombin O
- O
activated O
human O
platelets O
are O
forms O
of O
the O
estrogen B
receptor I
- I
related I
27 I
- I
kDa I
heat I
shock I
protein I
. O

This O
protein O
also O
binds O
to O
the O
immunoglobulin B
heavy I
- I
chain I
enhancer I
mu I
E1 I
site I
. O

An O
upstream B
segment I
contains O
tandem B
dinucleotide I
repeats I
( B
CT I
) I
19 I
/ I
( I
CA I
) I
16 I
. O

Levels O
of O
c B
- I
fos I
and I
c I
- I
jun I
transcripts I
remained O
elevated O
during O
periods O
of O
PKC B
activation O
and O
also O
returned O
to O
levels O
observed O
in O
control O
cells O
by O
30 O
- O
36 O
days O
, O
when O
the O
cells O
entered O
retrodifferentiation O
. O

In O
addition O
, O
cell B
- I
free I
synthesized I
hGR I
was O
capable O
of O
specific O
binding O
to O
glucocorticoid B
response I
element I
( I
GRE I
) I
- I
containing I
DNA I
fragments I
. O

Oligonucleotides O
containing O
the O
consensus B
GRE I
were O
the O
most O
efficient O
competitors O
, O
and O
fragments O
containing O
regulatory B
sequences I
from O
glucocorticoid B
- I
repressible I
genes I
were O
somewhat O
competitive O
, O
whereas O
single O
stranded O
oligonucleotides O
were O
unable O
to O
compete O
for O
mouse B
mammary I
tumor I
virus I
- I
long I
terminal I
repeat I
DNA O
binding O
, O
except O
when O
competitor O
was O
present O
at O
extremely O
high O
concentrations O
. O

Expression O
of O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptors I
on O
alveolar O
lymphocytes O
from O
patients O
with O
pulmonary O
granulomatous O
diseases O
. O

1 B
, I
25 I
( I
OH I
) I
2D3 I
receptors I
were O
expressed O
to O
a O
greater O
extent O
on O
CD8 O
+ O
T O
- O
lymphocytes O
than O
on O
CD4 O
+ O
T O
- O
lymphocytes O
in O
sarcoidosis O
, O
whereas O
a O
greater O
proportion O
of O
CD4 O
+ O
than O
of O
CD8 O
+ O
T O
- O
lymphocytes O
from O
patients O
with O
tuberculosis O
were O
receptor O
- O
positive O
. O

The O
NF B
kappa I
B I
independent I
cis I
- I
acting I
sequences I
in O
HIV B
- I
1 I
LTR I
responsive O
to O
T O
- O
cell O
activation O
. O

Activation O
of O
proenkephalin O
transcription O
by O
JunD B
is O
dependent O
upon O
a O
previously O
characterized O
cAMP B
- I
, I
phorbol I
ester I
- I
, I
and I
Ca I
( I
2 I
+ I
) I
- I
inducible I
enhancer I
, O
and O
JunD B
is O
shown O
to O
bind O
the O
enhancer B
as O
a O
homodimer B
. O

Third O
, O
TCF B
- I
1 I
bound O
specifically O
to O
a O
functional O
T B
cell I
- I
specific I
element I
in O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
- I
alpha I
) I
enhancer I
. O

However O
, O
blockade O
of O
the O
Ca B
( I
2 I
+ I
) I
- I
activated I
K I
+ I
channel I
is O
not O
associated O
with O
changes O
in O
cell O
- O
cycle O
gene O
activation O
, O
IL B
- I
2 I
production O
, O
IL B
- I
2R I
expression O
or O
B O
and O
T O
cell O
mitogenesis O
. O

From O
information O
available O
in O
the O
literature O
on O
the O
substrate O
specificity O
of O
the O
three O
enzymes B
, O
it O
is O
clear O
that O
a O
cysteine O
is O
not O
accepted O
in O
any O
of O
the O
S2 B
, I
S1 I
, I
S1 I
' I
, I
and I
S2 I
' I
subsites I
of O
cathepsin B
B I
and I
L I
, O
and O
not O
in O
the O
S1 B
and O
S1 B
' I
subsites O
of O
cathepsin B
D I
. O

Starting O
with O
a O
replication O
- O
incompetent O
molecular O
clone O
of O
human O
immunodeficiency O
virus O
type O
1 O
, O
lacking O
all O
the O
NF B
- I
kappa I
B I
and I
Sp1 I
binding I
sites I
present O
in O
the O
native B
long I
terminal I
repeat I
( O
LTR B
) O
, O
proviruses O
containing O
reconstructed B
LTRs I
with O
individual O
or O
combinations O
of O
NF B
- I
kappa I
B I
and I
Sp1 I
elements I
were O
generated O
and O
evaluated O
for O
their O
capacity O
to O
produce O
virus O
progeny O
following O
transfection O
- O
cocultivation O
. O

The O
human B
interferon I
beta I
( I
IFN I
- I
beta I
) I
regulatory I
element I
consists O
of O
multiple O
enhanson B
domains I
which O
are O
targets O
for O
transcription B
factors I
involved O
in O
inducible O
expression O
of O
the O
promoter B
. O

NF B
- I
kappa I
B I
activation O
by O
tumor B
necrosis I
factor I
alpha I
in O
the O
Jurkat O
T O
cell O
line O
is O
independent O
of O
protein B
kinase I
A I
, O
protein B
kinase I
C I
, O
and O
Ca B
( I
2 I
+ I
) I
- I
regulated I
kinases I
. O

Tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
mRNA I
production O
was O
analyzed O
by O
polymerase O
chain O
reaction O
amplification O
in O
monocytic O
U937 O
cells O
and O
in O
a O
chronically O
HIV O
infected O
U937 O
cell O
line O
( O
U9 O
- O
IIIB O
) O
. O

Several O
mutants O
derived O
from O
transformed O
human O
B O
cell O
lines O
are O
defective O
in O
expressing O
major B
histocompatibility I
complex I
( I
MHC I
) I
class I
II I
genes I
. O

When O
the O
human B
epsilon I
- I
or I
beta I
- I
globin I
genes I
driven O
by O
the O
dominant B
control I
region I
( O
DCR B
) O
are O
introduced O
into O
this O
system O
, O
the O
human B
epsilon I
- I
globin I
gene I
, O
in O
contrast O
to O
the O
beta B
- I
globin I
gene I
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR B
and O
is O
expressed O
strictly O
as O
an O
embryonic B
gene I
. O

In O
a O
fourth O
cell O
line O
, O
A1 O
- O
VDR O
, O
the O
receptor O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
had O
a O
low O
binding O
capacity O
and O
25 B
( I
OH I
) I
D3 I
- I
24 I
- I
hydroxylase I
activity O
was O
not O
detectable O
. O

Binding O
and O
elution O
properties O
to O
DNA O
- O
cellulose O
, O
however O
, O
differed O
from O
normal O
in O
both O
Ro O
- O
VDR O
and O
A1 O
- O
VDR O
cells O
where O
elution O
from O
DNA O
- O
cellulose O
occurred O
at O
a O
lower O
salt O
concentration O
than O
is O
typical O
of O
the O
1 B
, I
25 I
( I
OH I
) I
2D3 I
receptor I
. O

The O
defensin B
sensitivities O
of O
Salmonella O
typhimurium O
strains O
with O
mutations O
in O
the O
phoP B
/ I
phoQ I
two I
- I
component I
virulence I
regulon I
were O
tested O
by O
using O
purified B
defensins I
NP B
- I
1 I
and O
NP B
- I
2 I
. O

This O
implied O
that O
a O
pag B
( I
phoP I
- I
activated I
gene I
) I
product I
is O
responsible O
for O
defensin B
resistance O
. O

The O
two O
proteins O
differ O
by O
a O
14 B
- I
amino I
acid I
serine I
- I
rich I
insertion I
present O
in O
one O
of O
the O
CREB B
isoforms I
. O

Competition O
experiments O
did O
not O
reveal O
any O
high B
- I
affinity I
binding I
site I
for O
BSAP B
in O
known O
regulatory B
regions I
of O
immunoglobulin B
and I
class I
II I
major I
histocompatibility I
( I
MHC I
) I
genes I
, O
suggesting O
that O
BSAP B
is O
a O
regulator O
of O
a O
different O
set O
of O
B B
- I
lymphoid I
- I
specific I
genes I
. O

NF B
- I
kappa I
B I
as O
inducible O
transcriptional B
activator I
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
gene I
. O

The O
same O
agents O
induce O
transcription O
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
and I
interleukin I
- I
2 I
genes I
, O
depending O
on O
promoter B
elements I
that O
bind O
the O
inducible B
transcription I
factor I
NF B
- I
kappa I
B I
( O
or O
an O
NF B
- I
kappa I
B I
- I
like I
factor I
) O
. O

Fourth O
, O
extensive O
purification O
by O
several O
cycles O
of O
TRE B
- O
DNA O
affinity O
chromatography O
resulted O
in O
the O
32 B
, I
36 I
to I
42 I
and I
110 I
kD I
proteins I
and O
to O
less O
extent O
the O
50 B
kD I
factor I
. O

Activity O
of O
the O
immunoglobulin B
heavy I
and I
kappa I
light I
chain I
gene I
enhancers I
depends O
on O
a O
complex O
interplay O
of O
ubiquitous B
and I
developmentally I
regulated I
proteins I
. O

The O
internal O
methionine O
codons O
of O
human B
T I
- I
cell I
leukemia I
virus I
type I
II I
rex I
gene I
are O
not O
required O
for O
p24rex B
production O
or O
virus O
replication O
and O
transformation O
. O

Whereas O
c B
- I
Fos I
/ I
c I
- I
Jun I
heterodimers I
do O
not O
exist O
in O
B O
cells O
, O
they O
form O
and O
bind O
to O
the O
X2 B
- I
box I
in O
class O
II O
nonexpressing O
cells O
. O

A O
novel O
T B
- I
cell I
protein I
recognized O
the O
palindromic B
sequence I
within O
site B
B I
and O
also O
bound O
estrogen B
- I
or I
thyroid I
hormone I
- I
response I
elements I
with O
lower O
affinity O
. O

It O
has O
previously O
been O
shown O
that O
9S B
, O
untransformed B
progestin I
, I
estrogen I
, I
androgen I
, I
and I
glucocorticoid I
receptor I
complexes I
in O
rabbit O
uterine O
and O
liver O
cytosols O
contain O
a O
59 B
- I
kDa I
protein I
[ O
Tai O
, O
P O
. O
K O
. O
, O
Maeda O
, O
Y O
. O
, O
Nakao O
, O
K O
. O
, O
Wakim O
, O
N O
. O
G O
. O
, O
Duhring O
, O
J O
. O
L O
. O
, O
& O
Faber O
, O
L O
. O
E O
. O
( O
1986 O
) O
Biochemistry O
25 O
, O
5269 O
- O
5275 O
] O
. O

The O
expression O
vector O
was O
cotransfected O
with O
the O
chloramphenicol B
acetyl I
transferase I
( I
CAT I
) I
reporter I
gene I
regulated O
by O
the O
thymidine B
kinase I
promoter I
containing O
GAL4 B
DNA I
binding I
sites I
into O
NIH O
3T3 O
, O
293 O
, O
K562 O
, O
and O
Jurkat O
cell O
lines O
. O

Deoxycholate O
treatment O
of O
the O
cytoplasmic O
extract O
prepared O
from O
cells O
stimulated O
by O
TNF B
- I
alpha I
in O
the O
presence O
of O
Cu2 O
+ O
resulted O
in O
the O
release O
of O
NF B
kappa I
B I
from O
I B
kappa I
B I
alpha I
, O
indicating O
that O
Cu2 O
+ O
interferes O
with O
the O
dissociation O
of O
the O
NF B
kappa I
B I
- I
I I
kappa I
B I
complex I
. O

This O
novel O
enzyme O
is O
distinct O
from O
E6 B
- I
AP I
, O
the O
p53 B
- I
conjugating I
ligase I
, O
and O
from O
E3 B
alpha I
, O
the O
` B
` I
N I
- I
end I
rule I
' I
' I
ligase I
. O

IBR B
is O
a O
503 B
- I
amino I
- I
acid I
- I
long I
acidic I
protein I
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human B
NRF I
- I
1 I
/ I
alpha I
- I
Pal I
factor I
and O
highly O
related O
to O
the O
invertebrate O
transcription B
factors I
P3A2 B
and O
erected B
wing I
gene I
product I
( O
EWG B
) O
. O

IBR B
is O
a O
503 B
- I
amino I
- I
acid I
- I
long I
acidic I
protein I
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human B
NRF I
- I
1 I
/ I
alpha I
- I
Pal I
factor I
and O
highly O
related O
to O
the O
invertebrate O
transcription B
factors I
P3A2 B
and O
erected B
wing I
gene I
product I
( O
EWG B
) O
. O

Promoter O
function O
of O
the O
5 B
' I
flanking I
region I
of O
the O
thromboxane B
receptor I
gene I
was O
evaluated O
by O
transfection O
of O
thromboxane B
receptor I
gene I
promoter I
/ I
chloramphenicol I
acetyltransferase I
( I
CAT I
) I
chimera I
plasmids I
into O
platelet O
- O
like O
K562 O
cells O
. O

Full O
- O
length O
cDNAs B
and O
genomic B
clones I
were O
isolated O
, O
and O
the O
gene O
structure O
was O
determined O
. O
Comparison O
of O
the O
deduced O
amino O
acids O
shows O
88 O
% O
sequence O
identity O
between O
mouse B
and I
human I
BOB I
. I
1 I
/ I
OBF I
. I
1 I
. O

CD30 B
is O
a O
recently O
described O
member O
of O
the O
tumor B
necrosis I
factor I
/ I
nerve I
growth I
factor I
receptor I
superfamily I
. O

Many O
cytokines B
activate O
signal B
transducer I
and I
activation I
of I
transcription I
( I
STAT I
) I
transcription I
factors I
, O
which O
, O
in O
turn O
, O
activate O
transcription O
of O
inflammatory O
effector O
genes O
. O

Lymphoid B
enhancer I
- I
binding I
factor I
1 I
( O
LEF B
- I
1 I
) O
is O
a O
regulatory B
high I
mobility I
group I
( I
HMG I
) I
protein I
that O
activates O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
alpha I
) I
enhancer I
in O
a O
context O
- O
restricted O
manner O
in O
T O
cells O
. O

Lymphoid B
enhancer I
- I
binding I
factor I
1 I
( O
LEF B
- I
1 I
) O
is O
a O
regulatory B
high I
mobility I
group I
( I
HMG I
) I
protein I
that O
activates O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
alpha I
) I
enhancer I
in O
a O
context O
- O
restricted O
manner O
in O
T O
cells O
. O

